Beijing Northland Biotech

Privately held: no public share price

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
Hepatocyte growth factor (HGF)Gene therapy / editing
Atherosclerotic Cardiovascular Disease

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q3$7.3M—$17M$5.1Mreport ↗

Annual history (3 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$10M$6.1M—$6.3Mreport ↗

Beijing Northland Biotech reported revenue of $10.04M, up 19.0% YoY, R&D spend of $6.06M, and a quarterly net burn of $6.29M for fiscal year 2024.

Figures only: this period's report disclosed no narrative text

View 2 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2023-FY$8.4M—$14M$6.8Mreport ↗
2022-FY$9.6M$8.4M——report ↗